{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T12:07:25Z","timestamp":1790856445323,"version":"4.1.0"},"reference-count":39,"publisher":"Korean Cancer Association","issue":"3","license":[{"start":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T00:00:00Z","timestamp":1776902400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":["e-crt.org"],"crossmark-restriction":true},"short-container-title":["Cancer Res Treat"],"published-print":{"date-parts":[[2026,7,15]]},"abstract":"<jats:p>Major advances in the management of human epidermal growth factor receptor 2 (HER2)\u2013positive (HER2+) metastatic breast cancer (MBC) have been achieved through treatment intensification with novel HER2-targeted agents and combination strategies, resulting in substantial survival gains. However, indefinite exposure to systemic therapy imposes cumulative toxicity, financial strain, and quality-of-life burdens. In contrast, the concept of treatment de-escalation, aimed at maintaining disease control with less intensive therapy, has only recently emerged as a complementary paradigm. This review highlights two evolving avenues of treatment de-escalation. First, in hormone receptor\u2013positive\/HER2+ disease, randomized trials have demonstrated that combining HER2 blockade with endocrine therapy and cyclin-dependent kinase 4 and 6 inhibitors can overcome endocrine resistance, offering a chemotherapy-sparing approach with outcomes comparable to chemotherapy or antibody-drug conjugates. Second, in long-term responders, retrospective analyses and ongoing prospective trials are evaluating whether discontinuation of prolonged maintenance HER2 therapy can safely reduce treatment burden while preserving disease control, with the added potential for effective rechallenge upon relapse. Together, these developments suggest that treatment de-escalation represents a rational and necessary treatment strategy. Future progress will depend on biomarker-driven patient selection and prospective validation. Redefining success in HER2+ MBC to include not only survival but also quality of life and sustainability represents an important step toward patient-centered cancer care.<\/jats:p>","DOI":"10.4143\/crt.2025.1131","type":"journal-article","created":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T08:52:41Z","timestamp":1776934361000},"page":"697-708","update-policy":"https:\/\/doi.org\/10.4143\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Toward Sustainable Care in HER2-Positive Metastatic Breast Cancer: Emerging Evidence for Treatment De-escalation"],"prefix":"10.4143","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9924-4547","authenticated-orcid":true,"given":"Matilda Xinwei","family":"Lee","sequence":"first","affiliation":[{"name":"Department of Haematology-Oncology, National University Cancer Institute, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5835-6419","authenticated-orcid":true,"given":"Soo Chin","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Haematology-Oncology, National University Cancer Institute, Singapore"},{"name":"Cancer Science Institute, National University of Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2954","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/nejm200103153441101","type":"journal-article"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1413513","type":"journal-article"},{"key":"ref3","first-page":"519","type":"journal-article","volume-title":"Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study","author":"Swain","year":"2020"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2010.209","type":"journal-article"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1530\/erc-18-0029","type":"journal-article"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-04-2569","type":"journal-article"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/0960-0760(90)90424-j","type":"journal-article"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6690196","type":"journal-article"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/s0959-8049(00)00395-6","type":"journal-article"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgo.2019.06.004","type":"journal-article"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-023-00533-2","type":"journal-article"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1128\/mcb.24.19.8681-8690.2004","type":"journal-article"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1810527","type":"journal-article"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1911149","type":"journal-article"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2017.73.7585","type":"journal-article"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1109653","type":"journal-article"},{"key":"ref17","first-page":"1929","type":"journal-article","volume-title":"Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer","author":"Andre","year":"2019"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2214131","type":"journal-article"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(20)30112-1","type":"journal-article"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-23-1209","type":"journal-article"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2024.42.16_suppl.1008","type":"journal-article"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.sabcs22-pd18-07","type":"journal-article"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.298","type":"journal-article"},{"key":"ref24","volume-title":"","author":"Metzger","type":"book"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1113216","type":"journal-article"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.0646","type":"journal-article"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-21-3435","type":"journal-article"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2025.43.16_suppl.1016","type":"journal-article"},{"key":"ref29","first-page":"2078","type":"journal-article","volume-title":"Systemic therapy for patients with advanced human epidermal growth factor receptor 2\u2013positive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline","author":"Giordano","year":"2014"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.01799","type":"journal-article"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2017-000202","type":"journal-article"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-019-05427-1","type":"journal-article"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.sabcs23-po2-20-01","type":"journal-article"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1158\/1557-3265.sabcs25-ps1-10-20","type":"journal-article"},{"key":"ref35","first-page":"1143","type":"journal-article","volume-title":"Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer","author":"Cortes","year":"2022"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03021-7","type":"journal-article"},{"key":"ref37","first-page":"551","type":"journal-article","volume-title":"Trastuzumab deruxtecan plus pertuzumab for HER2-positive metastatic breast cancer","author":"Tolaney","year":"2026"},{"key":"ref38","first-page":"P5","type":"journal-article","volume-title":"Abstract P5-03-11: DEMETHER: a single-arm phase II trial to evaluate the efficacy and safety of subcutaneous pertuzumab and trastuzumab maintenance after induction treatment w\/ trastuzumab deruxtecan (T-DXd) for previously untreated HER2-positive advanced breast cancer","author":"Cortes","year":"2025"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt274","type":"journal-article"}],"container-title":["Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/e-crt.org\/upload\/pdf\/crt-2025-1131.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/e-crt.org\/journal\/view.php?doi=10.4143\/crt.2025.1131","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/e-crt.org\/upload\/pdf\/crt-2025-1131.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T08:30:10Z","timestamp":1783931410000},"score":1,"resource":{"primary":{"URL":"http:\/\/e-crt.org\/journal\/view.php?doi=10.4143\/crt.2025.1131"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,7]]}},"URL":"https:\/\/doi.org\/10.4143\/crt.2025.1131","relation":{},"ISSN":["1598-2998","2005-9256"],"issn-type":[{"value":"1598-2998","type":"print"},{"value":"2005-9256","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"assertion":[{"value":"2025-10-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-23","order":2,"name":"published","label":"Published online","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-15","order":3,"name":"published","label":"Print publication","group":{"name":"publication_history","label":"Publication History"}}]}}